Market Place
Sourcing Support
Fate Therapeutics Announces Leadership Transition
29 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics to Present at December Investor Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Highlights FT522 Off-the-Shelf CAR NK Cell at ACR
18 Nov 2024 //
GLOBENEWSWIRE
Fate Presents 6-Month Follow-Up Data in Autoimmunity Study
18 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Reports Q3 2024 Financial Results & Updates
12 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Highlights FT825 CAR T-cell Data at SITC 2024
09 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Preclinical Data on FT836 CAR T at SITC Meeting
08 Nov 2024 //
GLOBENEWSWIRE
Fate Therapeutics Reports Inducement Grant Nasdaq LR5635(c)(4)
04 Nov 2024 //
GLOBENEWSWIRE
Fate Reports Employee Inducement Awards Under Nasdaq LR 5635(c)(4)
02 Oct 2024 //
GLOBENEWSWIRE
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
12 Sep 2024 //
GLOBENEWSWIRE
Fate Therapeutics Reports Q2 2024 Results And Business Updates
13 Aug 2024 //
GLOBENEWSWIRE
Fate Therapeutics Reports New Employee Inducement Under Nasdaq Listing Rule
02 Aug 2024 //
GLOBENEWSWIRE
Fate Therapeutics Appoints Neely Mozaffarian To Board
31 Jul 2024 //
GLOBENEWSWIRE
Fate Therapeutics Reports New Employee Inducement Awards
02 Jul 2024 //
GLOBENEWSWIRE
Fate Therapeutics: New Employee Inducement Awards Per Nasdaq Rule
04 Jun 2024 //
GLOBENEWSWIRE
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Fate Therapeutics First Lupus Patient In FT819 CAR-T Study
09 May 2024 //
GLOBENEWSWIRE
Fate Therapeutics Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Fate To Host Q1 2024 Results, Operational Updates Webcast
06 May 2024 //
GLOBENEWSWIRE
Fate Presents FT522 Autoimmune Preclinical Data At ASGCT
03 May 2024 //
GLOBENEWSWIRE
Fate`s FT819 Autoimmune PoC Data At ASGCT Meeting
22 Apr 2024 //
GLOBENEWSWIRE
Fate Thera to Present at 23rd Annual Needham Virtual Healthcare Conference
03 Apr 2024 //
GLOBENEWSWIRE
Fate Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
GLOBENEWSWIRE
Fate Therapeutics Announces Pricing of $100 M Underwritten Offering
19 Mar 2024 //
GLOBENEWSWIRE
Fate Reports Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
05 Mar 2024 //
GLOBENEWSWIRE
Fate Therapeutics to Present at Upcoming March Investor Conferences
01 Mar 2024 //
GLOBENEWSWIRE
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter Results
15 Feb 2024 //
GLOBENEWSWIRE
Fate Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Fate Therapeutics Announces Initiation of Phase 1 Trial for FT825 / ONO-8250
08 Jan 2024 //
GLOBENEWSWIRE
Fate Reports Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Dec 2023 //
GLOBENEWSWIRE
Fate Therapeutics Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Fate Therapeutics to Present at Upcoming September Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Fate Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Fate Therapeutics to Conference Reporting Second Quarter 2023 Financial Results
28 Jul 2023 //
GLOBENEWSWIRE
Fate Therapeutics to Present at Upcoming June Investor Conferences
31 May 2023 //
GLOBENEWSWIRE
Fate Therapeutics Reports 1Q 2023 Financial Results and Business Updates
03 May 2023 //
GLOBENEWSWIRE
Fate Therapeutics to Webcast Conference Call Reporting 1Q 2023 FYR
24 Apr 2023 //
GLOBENEWSWIRE
Fate Therapeutics to Present at Upcoming March Investor Conferences
03 Mar 2023 //
GLOBENEWSWIRE
Fate Therapeutics Reports Q4 and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Fate Therapeutics to Webcast Conference Reporting Q4 Financial Results
13 Feb 2023 //
GLOBENEWSWIRE
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen
06 Jan 2023 //
GLOBENEWSWIRE
Fate Features Novel Approaches to Eliminate Conditioning Chemotherapy
13 Dec 2022 //
GLOBENEWSWIRE
Fate Therapeutics Announces Safety Data of iPSC-derived CAR T-cell Therapy
10 Dec 2022 //
GLOBENEWSWIRE
Fate Therapeutics Highlights iPSC-derived CAR NK Cell Programs at 2022 ASH
10 Dec 2022 //
GLOBENEWSWIRE
Ono Exercises Option to HER2-targeted CAR T-Cell Product Candidate
07 Nov 2022 //
PRESS RELEASE
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2
07 Nov 2022 //
GLOBENEWSWIRE
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product
03 Nov 2022 //
GLOBENEWSWIRE
Fate Therapeutics Reports 3Q FYR and Highlights Operational Progress
03 Nov 2022 //
GLOBENEWSWIRE
Fate Therapeutics to Webcast Conference Call Reporting Q3 2022 Financial Results
24 Oct 2022 //
GLOBENEWSWIRE
Fate Therapeutics to Present Clinical&Preclinical Data for iPSC Product Platform
05 Oct 2022 //
GLOBENEWSWIRE
Fate Therapeutics to Participate at Upcoming September Investor Conferences
02 Sep 2022 //
GLOBENEWSWIRE
Fate Tx Announces PC Publication Highlighting Derivation of CD8?? T Cells
09 Aug 2022 //
GLOBENEWSWIRE
Fate Therapeutics Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
Fate Tx to Webcast Conference Call Reporting Q2 2022 Financial Results
25 Jul 2022 //
GLOBENEWSWIRE
Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
30 Jun 2022 //
GLOBENEWSWIRE
Fate Tx Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical
28 Jun 2022 //
GLOBENEWSWIRE
Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
03 Jun 2022 //
GLOBENEWSWIRE
Fate Therapeutics to Present at Upcoming May Investor Conferences
06 May 2022 //
GLOBENEWSWIRE
Fate Therapeutics Reports First Quarter 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
